## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of: Mayeresse et al

Serial No.: 10/533,464 Art Unit: 1648

Filing Date: March 3, 2006 Examiner: Blumel, Benjamin

For: Immunogenic Composition

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

[]

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 197.

37 CFR 1.97		
		Copies of the references are enclosed Copies of the references were submitted in parent application Serial No.
	[]	(37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
A.	[ ] OR	
	[X]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed <b>after</b> three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but <b>before</b> the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission

of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. []	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.		
In acc	ordance with the requirements of 37 CFR 1.97(d):		
Į	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; and the petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.		
Į	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filling of this statement; and the petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.		
[	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.		
[X] Please charge any required fees to Deposit Account No.07-1392.  [ ] A duplicate copy of this paper is attached.			
	Respectfully Submitted,		

/Eric J. Kron/ Eric J. Kron Attorney of Record Registration No. 45,941

Date: 19 Nov 09 Customer No. 23347 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-ITELE

Facsimile: (919) 483-7988